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Background & Aims—Rare cases of azithromycin-induced hepatotoxicity have been reported, 
with variable clinical and histological features. We characterized clinical features and outcomes of 
azithromycin-induced liver injury.
Methods—We identified patients with azithromycin-induced liver injury from the Drug-Induced 
Liver Injury Network Prospective Study who had causality scores of definite, highly likely, or 
probable. Demographic, clinical, and laboratory data and 6-month outcomes were examined.
Results—Eighteen patients (72% female; mean age, 37 years) had causality scores of definite 
(n=1), highly likely (n=9), or probable (n=8). Common presenting symptoms were jaundice, 
abdominal pain, nausea, and/or pruritus. For 16 patients, abnormal results from liver tests were 
first detected 14 days after azithromycin cessation (range, 9–20 days). The median duration of 
azithromycin treatment was 4 days (range, 2–7 days). The pattern of injury was hepatocellular in 
10 patients, cholestatic in 6 patients, and mixed in 2 patients. The mean peak level of alanine 
aminotransferase was 2127 IU/L, of alkaline phosphatase was 481 IU/L, and of total bilirubin was 
9.2 mg/dL. Liver histology showed ductopenia and veno-occlusive changes in a few cases. Two 
individuals had severe hypersensitivity cutaneous reactions. After 6 months, 8 patients had 
recovered, 4 had chronic injury, 1 died, and 1 underwent liver transplantation (outcomes were 
unavailable for 4 patients). Two of the patients with fatal or liver transplantation outcomes had 
preexisting chronic liver disease.
Conclusions—Azithromycin-induced liver injury occurs within 1–3 weeks after azithromycin 
initiation and is predominantly hepatocellular in nature. Although most patients recover fully, 
severe cutaneous reactions, chronic injury, and serious complications leading to death or liver 
transplantation can occur (ClinicalTrials.gov identifier, NCT00345930).
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Introduction
Drug-induced liver injury (DILI) is an important cause of liver disease in the United States, 
accounting for 1–2% of hospital admissions and 13% of cases of acute liver failure.1, 2 
Hepatotoxicity is one of the most common black-box warnings placed on medications and is 
a major cause for failure to receive initial regulatory approval or withdrawal following the 
initial approval. 3, 4 Although numerous therapeutic classes of agents can cause idiosyncratic 
DILI, antimicrobials are the most common class of drugs implicated and account for 45% of 
cases in the United States.5 The frequency of serious antibiotic-induced hepatotoxicity is 
low when compared to the very large number of prescriptions written each year, but 
population-based estimates suggest that it occurs at a frequency of 1 to 10 per 100,000 drug 
prescriptions.6–8 Among antibiotics, the macrolides (erythromycin, azithromycin and 
clarithromycin) are some of the most commonly used. Their potential for hepatotoxicity was 
initially recognized in animals9 and was later well documented in humans based upon 
reactions to various erythromycin derivatives.10, 11
Azithromycin, a semisynthetic macrolide derived from erythromycin approved in 1994, is a 
potent and generally well tolerated oral antibiotic and recently became the most frequently 
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prescribed antibiotic in the United States.12 Cytotoxic assays performed during drug 
development revealed minimal intrinsic hepatotoxicity.13 Large clinical trials using 
azithromycin reported acute, transient, asymptomatic increases in serum aminotransferase 
levels in 1–2% of patients but similar rates were also found in comparator arms.14 Rarely, 
clinically apparent liver injury from azithromycin has been reported, but only as isolated 
case reports.10, 15, 16 The injury appeared to be idiosyncratic with variable clinical 
presentations, usually cholestatic and often with immunoallergic features.15–20 No common 
clinical phenotype or signature pattern of liver injury could be identified from these single 
case reports.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established 
the Drug-Induced Liver Injury Network (DILIN) in 2003 with the primary objective to 
investigate the causative agents, clinical features, pathogenesis, causality assessment and 
outcomes of DILI in the United States.21 The ongoing DILIN Prospective Study enrolls 
eligible individuals with suspected DILI due to drugs or dietary supplements other than 
acetaminophen at multiple academic institutions throughout the United States.5, 22 In this 
report, we characterize the clinical and histological features and outcomes of acute liver 
injury due to azithromycin in a sizable number of individuals with high causality scores.
Methods
The study design of the DILIN prospective study has been described in previous 
publications and some cases included in this report have been included in previous 
reports.22, 23 Individuals meeting pre-specified eligibility criteria undergo an evaluation for 
competing etiologies in a structured fashion.22 The study protocol requires a follow-up visit 
at 6 months after the initial enrollment, and individuals meeting definition of chronic DILI 
are asked also to return for visits at 12 and 24 months.22 The overall diagnosis of DILI and 
the causal relationship between the implicated agent(s) and the liver injury event are 
adjudicated by the DILIN Causality Committee in a systematic fashion using expert 
consensus.22, 24 The strength of causal association between the implicated agent(s) and the 
liver injury event is graded as definite, highly likely, probable, possible and unlikely.22 A 
DILIN severity score is assigned for each case that ranges from 1 (mild as defined by serum 
enzyme elevations with bilirubin <2.5 mg/dL and INR <1.5), 2 (moderate, serum enzyme 
elevations and bilirubin ≥2.5 mg/dL or INR ≥1.5), 3 (moderate-hospitalized, serum enzyme 
elevations, bilirubin ≥2.5 mg/dL or INR ≥1.5 and hospitalization for liver injury), 4 (severe, 
bilirubin ≥2.5 mg/dL and signs of hepatic failure such as INR ≥1.5, ascites or hepatic 
encephalopathy), and 5 (liver transplantation within 6 months of onset or death due to liver 
injury).22
This current analysis included all patients with liver injury attributed to azithromycin who 
were enrolled between September 2004 and May 2013 assigned a causality score of definite, 
highly likely or probable (Figure 1). Demographic, clinical history and laboratory results 
were abstracted, and each case was individually analyzed by one of the authors (MM, RV, 
NC) with attention to latency, clinical presentation, severity, time course, progression to 
chronicity, need for transplant, and liver-related death. The pattern of liver injury was 
categorized on the basis of the R-value ([ALT value/ ULN ALT] / [Alk P value/ULN Alk 
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P]) at presentation, with R > 5 defined as hepatocellular, R < 2 as cholestatic, and 2< R <5 
as mixed.5 All co-authors had access to the study data and had reviewed and approved the 
final manuscript.
Statistical Analysis
The data analyses were performed by the Duke Clinical Research Institute, the data 
coordinating center of the DILIN. SAS v 9.2 was used to aid all analyses. Continuous 
variables were summarized with mean and standard deviation or median and interquartile 
range (IQR, 25th–75th). Categorical data were expressed as counts and proportions. 
Comparison between the hepatocellular and cholestatic groups was made using non-
parametric Mann-Whitney test.
Results
Patient Characteristics (Figure 1)
Eighteen individuals with definite (n=1), highly likely (n=9) and probable (n=8) DILI 
constituted the study cohort. While azithromycin was the only implicated agent in 13 cases, 
there was another implicated agent with a “possible” causality score in the remaining 5 cases 
(trimethoprim-sulfamethoxazole in two, MRC-6 (a body building supplement) and oral 
contraceptives in one and, trimethoprim and ibuprofen in one case each). As a result, the 
causality score specific for azithromycin as the etiology of liver injury was definite in 1, 
highly likely in 7 and probable in 10 individuals.
The mean patient age for the group was 37 years with a range of 1.7 to 76 years (Table 1), 
14 were adults and 4 were children (ages 1.7, 8, 11, and 14 years at onset of DILI). The 
majority were female (n=13, 72%) and non-Hispanic white (n=15, 83%), and the average 
body mass index was 25.2 kg/m2 (range 13 to 42 kg/m2). Alcohol consumption around the 
time of onset of liver injury was present in 6 patients with one patient drinking daily. Five 
patients had pre-existing liver conditions including non-alcoholic fatty liver disease in two 
and one each with alcohol-related liver disease, chronic graft-vs-host disease with secondary 
iron overload, or biliary atresia (Table 2). Of note, 6 subjects reported previous exposure to 
azithromycin (Table 2). The latency between starting azithromycin and onset of DILI was 
not different among these individuals as compared to 12 subjects who did not report prior 
exposure to azithromycin. All patients tested negative for acute hepatitis A, B and C. IgG 
antibody to hepatitis E virus (anti-HEV) was tested in 14 patients and Ig M anti-HEV in 5 
patients and were negative in all.
Clinical presentation and Type of Liver Injury
All patients were symptomatic at presentation and the most common presenting symptoms 
were jaundice (89%), abdominal pain (67%), nausea (61%) and pruritus (56%). The mean 
duration of azithromycin use was 4 days (2–7). The median time to onset of symptoms after 
initiating azithromycin was 17 days (IQR: 1–58 days) and the median duration from 
azithromycin initiation to identification of laboratory abnormalities indicative of DILI was 
21 days (IQR: 2–65 days). In 16 patients, liver test abnormalities were first identified after 
stopping azithromycin, with a median delay of 14 days (IQR: 9–20 days). Overall, at 
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enrollment, hepatocellular pattern of liver injury [R > 5] was more frequent (56%) than 
cholestatic (33%) or mixed pattern (11%).
A summary of the age, gender, pattern of liver injury, peak laboratory values, DILIN 
causality and severity scores and 6-month outcome of all 18 cases is shown in Table 2. 
There was no obvious clustering of severity or other clinical characteristics according to age 
or gender.
The comparison among hepatocellular, cholestatic and mixed cases showed no differences 
with respect to latency, total dose, age, gender, body mass index, alcohol use or symptoms. 
However, there were some differences with respect to presence of autoantibodies, severity 
and outcome. Patients with hepatocellular injury were more likely to have a positive ANA or 
ASMA than those with cholestatic or mixed hepatitis (50% vs. 0%), and were more likely to 
have a fatal outcome or require transplantation (20% vs. 0%) and evidence of chronic injury 
6 months after onset (30% vs. 17%). Features such as rash, fever and eosinophilia occurred 
in both groups at similar rates.
Two patients developed a severe cutaneous reaction, one with Stevens Johnson syndrome 
(SJS) (Patient 3) and one with toxic epidermal necrolysis (TEN) (Patient 6). Both were 
young (ages 11 and 20 years old), female, and had an initial hepatocellular pattern of liver 
injury (R-values 8.0 and 7.2), which subsequently evolved into a cholestatic pattern (R-value 
1.0 and 1.3). Both patients had evidence of chronic injury at 6-month follow up, and the 
child with SJS, whose liver injury was improving, died of respiratory failure 9 months after 
initial presentation, which developed as part of her multisystem adverse drug reaction.
Histology
Liver biopsies were performed in 8 individuals during the liver injury event at a median 
duration of 15 days (range: 2 – 497 days) after DILI onset (explant liver sample was also 
available in one patient). Three cases showed hepatitis (one with mild acute hepatitis, one 
with severe acute on chronic hepatitis and one with moderate chronic hepatitis) without 
evidence of visible cholestasis. Three cases showed cholestasis with variable degrees of 
inflammation: two were classified as acute cholestasis and one as cholestatic hepatitis. Of 
the two remaining cases, one showed zone-3 necrosis with veno-occlusive changes and one 
biopsy showed complex findings including marked hemosiderosis and nodular regenerative 
hyperplasia probably related to prior bone marrow transplant. Two cases showed striking 
ductopenia (less than 25% of portal areas with ducts)—one case with acute cholestasis and a 
second case on a follow-up biopsy of the patient with acute hepatitis on the initial biopsy 
(Figure 2A and B). Veno-occlusive changes and/or central venulitis were seen in three cases, 
which is unusually frequent for DILI (Figure 2C and D). For example, in a previous report, 
we observed veno-occlusive changes in only 4.2% of 249 cases of suspected DILI 25. Three 
cases showed increased numbers of intrahepatic eosinophils and none showed increased 
numbers of plasma cells. The explant showed massive hepatocellular necrosis with 
extensive ductular reaction and only mild residual inflammation. Veno-occlusive changes 
were present but may have been secondary to the hepatocellular injury. A follow-up liver 
biopsy was obtained in 3 patients - one, as noted above, showed ductopenia on a biopsy 
taken about 9 months after the first biopsy, the second showed persistence of chronic 
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hepatitis more than a year later, and the third follow-up biopsy was obtained 10 days after 
the initial biopsy and both biopsies showed zonal necrosis and veno-occlusive changes.
Outcomes
Six month follow up was available for 14 patients of whom 8 recovered from the liver 
injury, 4 had evidence of chronic injury, one died of multi-organ failure and one underwent 
liver transplantation (Table 2). In those who recovered, the resolution was usually prompt 
and evident within 2–5 weeks (Table 1). The median time for 50% reduction of peak serum 
total bilirubin was 12 days (8–27) days and median time for its normalization was 35 days 
(25–46).
Four patients (patients 1, 3, 6, and 11) met the definition of chronic DILI at 6 months after 
onset. Both individuals with severe cutaneous reactions developed chronic DILI. Three of 
them had hepatocellular injury and jaundice initially. At 6 months, all three had normal 
bilirubin levels but still had mild to moderate elevations in serum ALT or Alk P levels.
The two individuals with a fatal/liver transplant outcome within 6 months after DILI onset 
were elderly, had pre-existing chronic liver disease and presented with jaundice and a 
hepatocellular pattern of liver injury. In the first case (patient 15), a 60 year old woman with 
underlying nonalcoholic steatohepatitis was treated with azithromycin for three days for a 
respiratory tract infection and developed fatigue, anorexia, pain and nausea 4 days later, 
followed by jaundice and worsening of mental status. At presentation, serum bilirubin was 
13.8 mg/dL, ALT 1579 IU/L and Alk P 142 IU/L with an INR of 2.6. Because of 
progressive hepatic failure, she underwent liver transplantation one month after initial 
presentation. The second fatal case was a 76 year old man (patient 18) with history of daily 
alcohol abuse and chronic obstructive pulmonary disease who was treated with a four day 
course of azithromycin for acute bronchitis and developed nausea followed by jaundice one 
week later with initial serum bilirubin 7.2 mg/dL, ALT 8787 IU/L and Alk P 130 IU/L. 
Imaging of the liver showed a small liver with heterogeneous texture. He died one week 
later of multi-organ failure.
Discussion
Azithromycin is a semisynthetic macrolide antibiotic widely used in the treatment of mild to 
moderate sinopulmonary infections. Its popularity rests on its broad spectrum of activity, 
rapid oral absorption, once daily administration, tissue penetration and excellent tolerability. 
A typical regimen is 250 to 500 mg given once daily for 4 to 7 days. Liver injury has been 
reported in patients taking azithromycin but only rarely, and the published literature is 
confined to isolated case reports. The reported typical pattern of injury was cholestatic and 
the clinical course was usually benign, resembling reports of liver injury from erythromycin. 
Only rare published cases have been severe, fatal or resulted in chronic liver injury.15, 18, 26
The current study describes the clinical presentation, course and outcome of 18 cases of 
clinically apparent liver injury, prospectively identified and adjudicated as probably, highly 
likely or definitely due to azithromycin. While cases with hepatocellular injury outnumbered 
those with cholestatic pattern, in many regards the clinical pattern matched what has been 
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reported from isolated case reports in the literature. Importantly, the latency to onset is 1–3 
weeks, and in 16 patients it was recognized two weeks after stopping azithromycin. Typical 
symptoms were fatigue, nausea, and abdominal pain followed by itching and jaundice. The 
onset of symptoms typically occurred after the course of azithromycin had been completed 
with only 2 of the 18 individuals developing jaundice while taking azithromycin. In 
addition, recovery was usually prompt, averaging 2 to 5 weeks and usually followed by 
complete resolution with completely normal serum enzymes and no symptoms or signs of 
persistent liver disease.
However, there were three major exceptions to the usual benign outcome of azithromycin 
induced liver injury. These outcomes took three forms: (1) severe hypersensitivity related 
cutaneous reactions with accompanying liver injury, (2) evolution into chronic cholestatic 
liver injury with vanishing bile duct syndrome, and (3) acute liver failure.
Two young women developed severe cutaneous hypersensitivity reactions following short 
courses of azithromycin, one fulfilling the criteria for Stevens-Johnson syndrome (SJS) and 
one as the more severe but related syndrome of toxic epidermal necrolysis (TEN). These 
dramatic syndromes have been reported with several medications, but most typically 
allopurinol, carbamazepine, lamotrigine, nevirapine, phenytoin, and phenobarbital.27–29 
These severe skin reactions have also been linked to macrolides (erythromycin, 
azithromycin and clarithromycin) but at a much lower frequency.27, 29–31 The rash generally 
arises within 1 to 28 days of starting therapy and is followed by involvement of other 
organs, such as liver, lung, kidney or bone marrow.28 The liver injury associated with SJS 
and TEN is usually mild and overshadowed by the cutaneous manifestations. However, the 
liver involvement can be severe and in both of the current cases, evidence of chronic injury 
was present. One patient died, although not from liver injury. Thus, azithromycin should be 
considered as a potential cause of SJS or TEN.
Another uncommon outcome of azithromycin induced liver injury is chronic, vanishing bile 
duct syndrome, which typically arises after an episode of severe acute cholestatic injury.18 
After the acute symptoms begin to resolve, jaundice and pruritus worsen and persist. Liver 
biopsy typically shows marked cholestasis and relative paucity of intralobular bile ducts 
(ductopenia). The prognosis is variable; some patients ultimately recover with resolution of 
jaundice and symptoms, although frequently with persistence of mild serum enzyme 
elevations and liver biopsy findings of relative ductopenia. Other patients with vanishing 
bile duct syndrome develop severe ductopenia and biliary cirrhosis, and ultimately require 
liver transplantation because of intractable pruritus, jaundice and hepatic dysfunction.32
The most ominous outcome of azithromycin induced liver injury is acute liver failure which 
seems to occur very infrequently.2, 33 For example, Mindikoglu et al., in their analysis of 
liver transplantation procedures performed for drug-induced acute liver failure in the United 
States did not find any instances of azithromycin induced ALF which required liver 
transplantation.33 In a recent report from the United States Acute Liver Failure Study Group, 
Reuben et al., described one patient who developed ALF due to a combination of 
trimethoprim/sulfamethoxazole and azithromycin.2 In the current case series, two patients 
developed acute liver failure with one dying and another requiring liver transplantation 
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yielding an overall severe adverse event rate of 11%. Both of these patients presented with 
hepatocellular liver injury and jaundice, befitting of “Hy’s Law”, which states that the 
mortality rate of drug-induced liver injury with a hepatocellular pattern and jaundice is 
likely to be greater than 10%. Indeed, in the current series, 10 patients fit the criteria for 
Hy’s Law yielding a mortality/transplant rate of 20%. On the other hand, the two patients 
with severe adverse events (one liver transplantation, one death), had underlying, pre-
existing liver disease (one was alcoholic and one had nonalcoholic steatohepatitis). Both 
patients were more than 60 years old and presented with a clinical syndrome of “acute-on-
chronic” liver failure.
In conclusion, azithromycin-induced liver injury typically occurs within 2–3 weeks of 
exposure and presents with predominantly hepatocellular pattern of injury and rarely severe 
cutaneous skin reactions. Liver histology may demonstrate ductopenia and veno-occlusive 
changes. Two individuals had a severe hypersensitivity cutaneous reaction. Although full 
recovery occurred in the majority of the cases, chronic DILI and serious outcomes (death 
and liver transplantation) developed in a minority of patients. Individuals with underlying 
chronic liver disease may be at higher risk for fatal outcomes from azithromycin induced 
liver injury, emphasizing that drugs should be prescribed to such patients with care and for 
good cause.
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Individual Case Histories
Case 4: Acute self-limited cholestatic hepatitis due to azithromycin
A 13-year-old male with no significant past medical history diagnosed with streptococcal 
pharyngitis was prescribed azithromycin for 5 days. Six days after finishing azithromycin 
treatment, he developed pruritus on both hands and feet that extended to the rest of the body; 
this was followed by jaundice and coluria. The patient was noted to have a cholestatic 
pattern of liver injury; there was no eosinophilia. He denied use of herbal supplements or 
taking any other medications around the time of onset. BMI was 19.5 kg/m2. Work up for 
competing etiologies included hepatitis A, B, C, E serologies, ANA and ASMA, all of which 
were negative. Abdominal imaging was remarkable for a normal liver and splenomegaly.
A liver biopsy performed about 6 weeks after presentation revealed no portal or periportal 
inflammation; hepatic parenchyma showed diffuse canalicular cholestasis. There were 
occasional groups of macrophages that marked areas of hepatocyte dropout. Acidophil 
bodies were not seen. There were scattered eosinophils, but no increase in lymphocytes. 
Plasma cells were not present. Trichrome and reticulin stains confirmed absence of 
underlying chronic disease.
The patient was not rechallenged, did not receive steroids, nor required a liver transplant. He 
was lost to follow up.
Martinez et al. Page 10
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2016 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Time* ALT
(U/L)
AST
(U/L)
Alk P
(U/L)
Bilirubin
(mg/dL)
INR Comments
2 w 73 47 411 4.3 n/a Initial liver tests, R = 1.7
2 w 79 61 395 5.3 0.97 Peak Bilirubin
6 w 223 122 333 3.0 n/a Around time of liver biopsy
8 w 262 125 311 1.9 1.0 Peak ALT and R-ratio
Bilirubin < 50% of Peak value
*
time in weeks (w) after azithromycin initiation. Alk P: alkaline phosphatase. n/a: not available.
Comment: This is a typical example of self-limited, mild-to-moderate cholestatic liver 
injury secondary to Azithromycin. The case was judged as very likely due to azithromycin.
Case 6: Acute toxic epidermal necrolysis with accompanying liver injury 
due to azithromycin
A 20-year-old African American woman without significant past medical history received a 
5-day course of azithromycin for an upper respiratory tract infection. Two days later, she 
returned to the emergency room with worsening symptoms, new facial swelling, jaundice 
and a pruritic rash. She was also taking ibuprofen around the time of symptom onset. After 
evaluation, the patient was admitted to the Intensive Care Unit (ICU) given concern for toxic 
shock syndrome. The rash was initially limited to the truncal area, but then became 
generalized and led to blisters over the palms and involvement of mouth and vagina. 
Laboratory data showed abnormal liver tests with a hepatocellular pattern of injury and no 
eosinophilia.
Diagnostic evaluation included negative tests for hepatitis A, B, C, E as well as 
cytomegalovirus, herpes simplex virus, Epstein Barr Virus and human immunodeficiency 
virus infections, leptospirosis, legionella and Rocky Mountain spotted fever. Serum ANA 
was positive at a titer of 1:2560; but immunoglobulin levels were normal and anti-double 
stranded DNA was negative. Liver imaging was unremarkable.
The clinical course was complicated by acute respiratory distress syndrome with multi-
system organ dysfunction; Skin biopsy revealed toxic epidermal necrolysis. She received 
intravenous immunoglobulin (IVIG), methylprednisolone, daptomycin, piperacillin-
tazobactam, cefazolin, clindamycin, ceftriaxone and transient extra-corporeal membrane 
oxygenation during her ICU stay.
A liver biopsy 1 week after presentation revealed central zone cholestasis with intact portal 
tracts and bile ducts. Repeat liver biopsy because of persistently abnormal liver tests around 
12 weeks after initial presentation showed marked lobular cholestasis with hepatocyte injury 
and prominent sinusoidal debris, evolving ductopenia without significant fibrosis or 
hepatitis.
At 6th and 24th month follow ups, her liver tests were still abnormal with a cholestatic 
pattern of injury.
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Time* ALT
(IU/L)
AST
(IU/L)
Alk P
(IU/L)
T. Bili
(mg/dL)
INR Comments
2 d 140 239 71 3.7 1.1 Initial Liver tests
3 d 169 352 35 3.5 1.1 Peak R-ratio
4 d 266 376 69 3.7 3.08 First ALT Peak
1 w 177 163 190 6.1 1.1 Liver biopsy
2 w 50 108 148 8.0 n/a
3 w 172 181 718 15.9 n/a Peak Alk P
4 w 237 230 522 20.0 n/a Peak Bilirubin
6 w 175 152 323 13.4 1.1 Alk P < 50% of Peak value
8 w 410 333 557 16.0 1.1
12 w 1351 1074 345 11.6 1.1 Second Peak ALT
12 w 586 276 286 10.3 1.0 ALT < 50% of 2nd peak value
16 w 237 171 252 9.4 n/a Bilirubin < 50% of peak value
12 m 311 227 406 1.3 1.0
*
time in days (d), weeks (w) or months (m) after azithromycin initiation. Alk P: alkaline phosphatase. n/a: not available.
Comment: This patient developed a severe cutaneous reaction to azithromycin 
accompanied by an acute hepatitis with jaundice that evolved into a cholestatic pattern of 
injury and prolonged jaundiced followed by persistence of abnormal liver tests 1 year after 
initial onset. This case was judged to be very likely (2) due to azithromycin.
Case 16: Acute hepatocellular injury after a short course of azithromycin 
with evidence of persisting chronic injury 1 and 2 years later
A 61-year-old non-Hispanic white man received a 5-day course of azithromycin for an upper 
respiratory tract infection. His other medical problems included diabetes mellitus, obesity 
and hyperlipidemia. Three days after azithromycin was stopped, he developed nausea, 
vomiting, generalized fatigue, myalgias and arthralgias. Two weeks later he sought medical 
care and was found to be jaundiced with marked elevations in serum aminotransferase levels 
(Table). He denied a known history of liver disease, alcohol intake or use of herbal 
supplements around the time of onset. Other medications included repaglinide, 
hydrochlorothiazide/triamterene, insulin, esomeprazole, metoprolol and acetaminophen 
(<2.5 grams of acetaminophen daily). Work up for competing etiologies included hepatitis 
A, B, C and E serologies, ANA and ASMA, all of which were negative. Liver ultrasound 
was remarkable for hepatomegaly and steatosis. A Computerized tomography (CT) scan of 
the abdomen revealed ascites, mild splenomegaly and mild hepatomegaly.
A liver biopsy was performed 11 months later given persistent of abnormal liver tests; the 
findings of the liver biopsy were cirrhosis with features suggesting underlying 
steatohepatitis (NASH) and scattered eosinophils. It was considered that patient had 
underlying non-alcoholic fatty liver disease and this may have had accentuated the 
presentation of drug induced liver injury from azithromycin
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The patient was not rechallenged, did not receive steroids, nor has required a liver 
transplant.
Time* ALT
(U/L)
AST
(U/L)
Alk P
(U/L)
T.Bili
(mg/dL)
INR Comments
2 w 1492 2359 n/a 6.7 n/a Initial Liver tests
3 w 4064 4852 473 9.5 n/a Peak ALT and Alk P; R =16
4 w 425 209 351 19.1 1.2 ALT, Alk P, < 50% of peak values
5 w 80 96 279 20.2 n/a Peak Bilirubin
8 w 42 75 234 9.3 1.2 Bilirubin < 50% of peak value
12 w 23 44 249 3.8 1.1
20 w 32 41 238 1.8 1.1
24 w 34 44 233 1.3 1.1
11 m 33 36 182 1.3 n/a Liver Biopsy
16 m 41 47 195 1.6 1.1
24 m 32 49 168 0.8 n/a
*
time in weeks (w) or months (m) after azithromycin initiation. Alk P: alkaline phosphatase. n/a: not available.
Comment: This patient developed an acute hepatitis-like syndrome due to azithromycin 
with a short latency period and prolonged course. Imaging suggests that he had a pre-
existing cirrhosis probably due to nonalcoholic steatohepatitis and presented with an “acute-
on-chronic” clinical onset and had residual evidence of liver injury 1 and 2 years later. This 
case was judged as being very likely (2) due to azithromycin.
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Figure 1. 
Study flow describing number of azithromycin cases and their salient characteristics among 
all cases enrolled into the DILIN Prospective Study
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Figure 2. 
Liver histology in patients with azithromycin hepatotoxicity. A. (Patient 3) An 11 year old 
Caucasian female with azithromycin hepatotoxicity underwent a liver biopsy at 20 days after 
DILI onset. Ductopenic portal area with mild inflammation. B. Zone 3 cholestasis with both 
hepatocellular and canalicular (arrows) bile accumulation. (A and B taken from the same 
case, both H&E, 600×). C. (Patient 11) A 45 year old Caucasian male with azithromycin 
hepatotoxicity underwent a liver biopsy at day 139 after DILI onset. Chronic hepatitis with 
perivenular inflammation and hemorrhage. (P – Portal area; V – Vein; H&E 200×). D. 
(Patient 10) Mild veno-occlusive changes. There is a layer of fibroinflammatory tissue 
inside the vein (arrowheads). (Masson trichrome, 600×).
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Table 1
Demographic and clinical characteristics of individuals with Azithromycin induced liver injury (N=18)
Characteristic Azithromycin induced liver injury (N=18)
Age (years) 37 (1.7, 76.1)
Female, n (%) 13 (72.2)
Self-reported race, n (%)
  Caucasian 17 (94.4)
  Black 1 (5.6)
Hispanic, n (%) 2 (11.1)
BMI (kg/m2) 25.2 (13.2, 42.4)
Latency [median (25th, 75th)]
  Drug start to onset of symptoms 17 (1,58)
  Drug start to DILI onset 21 (2, 65)
  Drug stop to DILI onset 17 (1, 57)
Types of Liver Injury at Onset
  Cholestatic 6 (33)
  Mixed 2 (11)
  Hepatocellular 10 (56)
Signs and Symptoms, n (%)
  Jaundice 16 (89)
  Abdominal pain 12 (67)
  Nausea 11 (61)
  Pruritus 10 (56)
  Rash€ 6 (33)
  Fever 5 (28)
Recovery of total bilirubin in those peak ≥ 2.5mg/dL [median (25th, 75th)]
  Days from peak to 50% reduction in total bilirubin 12 (8, 27)
  Days from peak to total bilirubin <2.5 mg/dL 35 (25, 46)
  Days from peak to 50% reduction in total bilirubin (non-chronic subjects) 12 (7,26)
Progression to chronicity, n (%) 4 (28.6)
Death from liver disease, n (%) 1 (5.6)
Liver transplant, n (%) 1 (5.6)
All values are expressed as mean with range unless otherwise specified. BMI: Body mass index.
€One case of toxic epidermal necrolysis and another of Stevens Johnson#x02019;s syndrome.
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